Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.68 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | PTPRB | P23467 | 1/20 | 0.57 |
| ▸ | CDC25A | P30304 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.57 |
| ▸ | PTEN | P60484 | 1/20 | 0.57 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315728 | 0.89 | SLC6A3 (0.63) | FFAR1TAAR1PKM | |
| SCHEMBL1205707 | 0.87 | MAPT (0.62) | FFAR1TAAR1PKM | |
| SCHEMBL7340106 | 0.86 | TAAR1 (0.57) | FFAR1TAAR1CASP3CASP7 | |
| SCHEMBL26343023 | 0.86 | FFAR1 (0.57) | FFAR1KEAP1TAAR1CASP3CASP7 | |
| SCHEMBL1206928 | 0.86 | MAPT (0.66) | FFAR1 | |
| SCHEMBL70271 | 0.86 | KEAP1 (0.74) | FFAR1KEAP1PTPRBCDC25ACDC25B | |
| SCHEMBL5308357 | 0.85 | FFAR1 (0.52) | FFAR1TAAR1CASP3CASP7 | |
| Phenyl Propionic Acid SCHEMBL28544542 | 0.84 | FFAR1 (0.59) | FFAR1KEAP1TAAR1 | |
| Hydrochloric Acid SCHEMBL10982620 | 0.84 | KEAP1 (0.71) | FFAR1KEAP1PTPRBCDC25ACDC25B | |
| SCHEMBL3054084 | 0.83 | FFAR1 (0.55) | FFAR1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132115-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | TIANJIN GUDUI BIO PHARM CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-4600244-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS, AND USES | Tianjin Gudui Bio-Pharm Co., Ltd. (CN) | 2025-08-13 | — | — | EP | claimed |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2025-05-20 | — | — | US | claimed |
| WO-2025057535-A1 | SEPARATION MEMBRANE | 日東電工株式会社 | 2025-03-20 | — | — | WO | claimed |
| CN-117143097-A | Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-12-01 | — | — | CN | claimed |
| US-20220194909-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2022-06-23 | — | — | US | claimed |
| EP-0077662-B1 | PREPARATION OF NITROARYLACETIC ACID ESTERS AND DERIVATIVES THEREOF | ETHYL CORPORATION (US) | 1985-10-02 | — | — | EP | claimed |
| US-20260132115-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | TIANJIN GUDUI BIO PHARM CO LTD (CN) | 2026-05-14 | — | — | US | disclosed |
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2026-02-19 | — | — | US | disclosed |
| EP-4600244-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS, AND USES | Tianjin Gudui Bio-Pharm Co., Ltd. (CN) | 2025-08-13 | — | — | EP | disclosed |
| CN-116209433-B | Small molecule albumin binding agents | 俄勒冈健康科学大学 | 2025-05-23 | — | — | CN | disclosed |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2025-05-20 | — | — | US | disclosed |
| WO-2025057535-A1 | SEPARATION MEMBRANE | 日東電工株式会社 | 2025-03-20 | — | — | WO | disclosed |
| EP-0538134-B1 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMA (IL) | 1997-03-12 | — | — | EP | disclosed |
| WO-1996040097-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0743853-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1996-11-27 | — | — | EP | disclosed |
| US-5486541-A | FOR TREATING PARKINSON*S DISEASE, MEMORY DISORDERS, ALZHEIMER*S DISEASE, DEPRESSION OR HYPERACTIVE SYNDROME | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-01-23 | — | — | US | disclosed |
| WO-1995021612-A2 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0538134-A2 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-04-21 | — | — | EP | disclosed |
| US-4963563-A | TREATING GLAUCOMA; INHIBITORS OF ALPHA-2-ADRENERGIC RECEPTORS | ABBOTT LABORATORIES (US) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | OPRK1, OPRD1, OPRM1 | FFAR1 589/4885KEAP1 530/4885PTPRB 2410/4885 |
| US-20220194909-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | HSD11B1, HSD11B2, CYP11B1 | FFAR1 695/4885KEAP1 1504/4885PTPRB 2836/4885 |
| US-20260132115-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | BACE1, IL1B, CYP11B1 | FFAR1 110/4885KEAP1 2209/4885PTPRB 4136/4885 |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | HSD11B1, HSD11B2, HSD17B1 | FFAR1 623/4885KEAP1 1272/4885PTPRB 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.